相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
Philippe Conus et al.
SCHIZOPHRENIA BULLETIN (2018)
Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial
Zahra Sepehrmanesh et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2018)
Investigating the Interactive Effects of Sex Steroid Hormones and Brain-Derived Neurotrophic Factor during Adolescence on Hippocampal NMDA Receptor Expression
Cushla R. McCarthny et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2018)
Early Interventioned and a Direction of Novel Therapeutics for the Improvement of Fuctional Outcomes in Schizophrenia: A Selective Review
Masayoshi Kurachi et al.
FRONTIERS IN PSYCHIATRY (2018)
Drug discovery strategies and the preclinical development of D-amino-acid oxidase inhibitors as antipsychotic therapies
Bence Szilagyi et al.
EXPERT OPINION ON DRUG DISCOVERY (2018)
Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial
Chun-Yuan Lin et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2017)
Cognitive effects of adjunctive N-acetyl cysteine in psychosis
M. Rapado-Castro et al.
PSYCHOLOGICAL MEDICINE (2017)
Assessment of the Target Engagement and D-Serine Biomarker Profiles of the D-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756
Eimear Howley et al.
NEUROCHEMICAL RESEARCH (2017)
Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute D-cycloserine
Jennifer K. Forsyth et al.
SCHIZOPHRENIA BULLETIN (2017)
Linking early-life NMDAR hypofunction and oxidative stress inyschizophrenia pathogenesis
Giles E. Hardingham et al.
NATURE REVIEWS NEUROSCIENCE (2016)
Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials
Y. Iwata et al.
MOLECULAR PSYCHIATRY (2015)
Benzoate, a D-Amino Acid Oxidase Inhibitor, for the Treatment of Early-Phase Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
Chieh-Hsin Lin et al.
BIOLOGICAL PSYCHIATRY (2014)
The Selective Glycine Uptake Inhibitor Org 25935 as an Adjunctive Treatment to Atypical Antipsychotics in Predominant Persistent Negative Symptoms of Schizophrenia Results From the GIANT Trial
Joep H. Schoemaker et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2014)
Biological insights from 108 schizophrenia-associated genetic loci
Stephan Ripke et al.
NATURE (2014)
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia
Christine E. Marx et al.
PSYCHOPHARMACOLOGY (2014)
D-Cycloserine augmentation of cognitive remediation in schizophrenia
Christopher K. Cain et al.
SCHIZOPHRENIA RESEARCH (2014)
Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial
Fang Liu et al.
SCHIZOPHRENIA RESEARCH (2014)
Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy
Kee-Hong Choi et al.
BRITISH JOURNAL OF PSYCHIATRY (2013)
A Note on the Jadad Score as an Efficient Tool for Measuring Trial Quality
Kaitlin E. Palys et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study
Deepak C. D'Souza et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Add-on Treatment of Benzoate for Schizophrenia A Randomized, Double-blind, Placebo-Controlled Trial of D-Amino Acid Oxidase Inhibitor
Hsien-Yuan Lane et al.
JAMA PSYCHIATRY (2013)
Clozapine, but not haloperidol, enhances glial d-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes
Shunske Tanahashi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
A Multicenter, Add-On Randomized Controlled Trial of Low-Dosed-Serine for Negative and Cognitive Symptoms of Schizophrenia
Mark Weiser et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Glutamate signaling in the pathophysiology and therapy of schizophrenia
Chieh-Hsin Lin et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2012)
A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia
K. N. Roy Chengappa et al.
SCHIZOPHRENIA RESEARCH (2012)
The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project
A. Wimo et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2011)
Stigmatization of schizophrenia as perceived by nurses, medical doctors, medical students and patients
G. Serafini et al.
JOURNAL OF PSYCHIATRIC AND MENTAL HEALTH NURSING (2011)
Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis
Guochuan E. Tsai et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Yechiel Levkovitz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
MECHANISMS OF DISEASE Alzheimer's Disease
Henry W. Querfurth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
Christine E. Marx et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Memory and the NMDA Receptors
Fei Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
PLOS MEDICINE (2009)
N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial
Michael Berk et al.
BIOLOGICAL PSYCHIATRY (2008)
Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection
Jeffrey A. Lieberman et al.
PHARMACOLOGICAL REVIEWS (2008)
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
Donald C. Goff et al.
NEUROPSYCHOPHARMACOLOGY (2008)
The Cognitive and Negative Symptoms in Schizophrenia, Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
Robert W. Buchanan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
N-acetylcysteine and neurodegenerative diseases: Basic and clinical pharmacology
Motoki Arakawa et al.
CEREBELLUM (2007)
Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia
MR Stefani et al.
BIOLOGICAL PSYCHIATRY (2005)
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
MF Green et al.
BIOLOGICAL PSYCHIATRY (2004)
Effects of D-cycloserine on negative symptoms in schizophrenia
EJ Duncan et al.
SCHIZOPHRENIA RESEARCH (2004)
Glutamate as a therapeutic target in psychiatric disorders
DC Javitt
MOLECULAR PSYCHIATRY (2004)
Modeling the early course of schizophrenia
H Hafner et al.
SCHIZOPHRENIA BULLETIN (2003)
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia
DC Goff et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2001)
Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia
HM Ibrahim et al.
AMERICAN JOURNAL OF PSYCHIATRY (2000)
Glutamate receptor expression in schizophrenic brain
JH Meador-Woodruff et al.
BRAIN RESEARCH REVIEWS (2000)